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sive drugs, patients would be expected to have filled med-
ications documented in medical records within the “filled
as intended” time frame. This simple analysis further il-
lustrates that patients frequently do not comply with med-
ication taking for chronic, asymptomatic conditions.
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OBJECTIVE: The purpose of this study was to determine
the impact on quality of life, level of compliance and sat-
isfaction with services after pharmacist outpatient coun-
seling and monitoring.
METHOD: The study is a prospective examination of hy-
pertensive patients over 64 years old. The control group
(N  160) received standard drug counseling on receiv-
ing new medication. The treatment group (N  144) re-
ceived extensive drug education and monthly follow-up
calls for reassessment and to reinforcing compliance. The
patients filled out health status surveys at the start of the
study (T0), in 6 months (T1) and 12 months later (T2). The
survey instruments included Pharmacy Services satisfac-
tion, the Morisky Compliance Scale, medication aware-
ness, smoking, liquor, Likert Scale self-assessment of glo-
bal health (0–100 in 10-unit decrements), SF-36, HUI
Mark 2, and the Hypertension/Lipid TyPE Survey.
RESULTS: The groups were compared to each other at T0
and T2, and compared to themselves from T0 to T2. The
difference between groups in Morisky Score and Likert
Scale was not significant and neither group had significant
changes. At T2 the treatment group had a higher SF-36 RE
score than the control group, 79.06 versus 67.42 (p 
0.05) while other scales showed no significant differences
between groups or changes over time. The difference be-
tween groups in HUI attributes or utility score was not sig-
nificant and neither group had significant changes.
CONCLUSION: Patient counseling does not appear to
enhance compliance in this population. QoL scores indi-
cate some emotional benefit, possibly due to ongoing
pharmacist contact. Other measures in this population
suggest no impact on overall level of health based on out-
patient counseling.
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Patient compliance with their medication regimen is es-
sential for the success of their medical therapy, especially
in the treatment of chronic illnesses.
OBJECTIVE: The purpose of the present study is to iden-
tify factors that influence patient perceived compliance in
accordance to patient’s health belief perspective.
METHOD: This study employed a stratified random sam-
ple of 7000 patients from southern California, served by a
large health maintenance organization (Kaiser Perma-
nente). The dependent variable was derived from a well-
validated self-reported (Morisky) scale for patient adher-
ence in medication regimen. First a restrictive binary
choice logistic model was made where patients were differ-
entiated on basis of their compliance or noncompliance.
Next, patient’s compliance behavior was categorized as
High, Medium, or Low, and an ordered probit model was
employed. Patient’s socioeconomic status, comorbidities,
prescription utilization pattern were used as explanatory
variables.
RESULTS: The study sample consisted of patients 34 to 82
years of age (mean  50). Both restrictive and relaxed
models showed that likelihood of poor or medium compli-
ance significantly (p  0.0001) increased with age. Female
patients, African Americans, and employed persons were
likely to have more compliant behavior. Patient health be-
haviors (smoking, drinking) or education did not show any
significant contribution to prediction. Patients with high
physical or mental SF-36 component scores and fewer
chronic diseases were found poorly compliant. Model
fit was evaluated by adjusted generalized R2 (0.1348) as
well as by ROC curves (sensitivity [25.7%] and specific-
ity [99.5%]).
CONCLUSION: Findings of this study reconfirmed the
usefulness of the health belief model in determining fac-
tors affecting compliance.
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The majority of diagnosed hypertensive patients receive
drug therapy in addition to recommended lifestyle changes.
One of the major barriers to the management of hyper-
tension is the interruption or premature termination of
therapy.
OBJECTIVE: To estimate the prevalence of, and health-
care costs associated with, the discontinuation of anti-
hypertensive drug therapy in a Medi-Cal population.
METHODS: The Medi-Cal paid claims data were used
to identify patients with at least one anti-hypertensive
prescription. The date of this first prescription was used
to partition the patient’s stream of paid claims into pre-
and post-time periods of 6 and 12 months, respectively.
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Medi-Cal data were available on an 11-year time span
(July 1985–December 1996). Only the first episode of
treatment for each patient was considered. Patients were
further excluded if they were pregnant, they were in long-
term facilities before and at the keydate, and if they lost
their Medi-Cal eligibility during the study period.
RESULTS: In this study 30,200 patients met the eligibility
criteria (mean age 60.8  19.4, 67.1% female). Among
patients, 20.8% started their therapy with a calcium-
channel-blocker, 18.7% with a diuretic, and 18.6% with
a beta-blocker. Before the end of the study period, 94.2%
of patients either discontinued or interrupted their anti-
hypertensive medications. Average cost in the post-period
(e.g., hospital, ambulatory care, and all other costs but
prescription and long-term care) was $7945 for discon-
tinuing versus $7525 for continuing patients (Wilcoxon-
rank-sums test, p  0.0354).
CONCLUSIONS: Patients who interrupt their anti-
hypertensive medications cause a higher healthcare ex-
penditure than continuous patients. Further analyses are
needed considering co-factors that may influence health-
care utilization.
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OBJECTIVE: To compare the effects of hydroxymethyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) with non-statins on compliance duration, health-
care utilization, and healthcare costs in an health mainte-
nance organization (HMO) population.
METHODS: A retrospective cohort study was performed
using claims data and survey data in continuously en-
rolled patients (n  810) with prescriptions for antihy-
perlipidemic medications from April 1993 to March
1995. Compliance duration was defined as the duration
of over 80% compliance with antihyperlipidemic medica-
tions, healthcare utilization measures as hospital admis-
sions due to cardiac diseases and outpatient visits, and
healthcare cost variables as total healthcare costs, net
costs, and drug cost. Each main outcome measure was
modeled (Tobit model for compliance duration, probit
model for healthcare utilization, and OLS model for
healthcare costs).
RESULTS: The statins significantly prolonged the com-
pliance duration (p  0.05). The factors significantly in-
fluencing on compliance duration were female gender,
baseline high compliance, chronic disease scores, number
of cholesterol-lowering drugs in the regimen, and diag-
nostic characteristics such as peripheral vascular diseases
(PVD), cardiac diseases (CVD), hypertension, and diabe-
tes. The statins significantly decreased adjusted hospital
admissions due to CVD in year 1 (p  0.05) especially in
those patients with PVD (p  0.01) and CVD (p  0.05).
There was no significant difference in total healthcare
costs in year 1 between patients on statins and those on
non-statins. However, in year 2 and pooled data (year 1
and year 2), the statins were significantly associated with
higher total healthcare costs (p  0.05, p-pooled  0.05)
and higher drug costs (p  0.0001, p-pooled  0.0001).
CONCLUSIONS: The statins improved patient’s compli-
ance of antihyperlipidemic therapy. The statins also de-
creased the hospital admissions due to CVD without signif-
icantly elevated healthcare costs in the short term (year 1).
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The ultimate goal of pharmaceutical care is to improve
patient HRQoL. Although researchers have attempted
successfully to link pharmaceutical care behaviors with
HRQoL, the findings are not consistent. Furthermore,
the role of patient satisfaction and compliance in this re-
lationship needs to be explored.
OBJECTIVE: To test a path analytic model depicting the
association of pharmacists’ directive guidance behaviors,
patient satisfaction, compliance, and HRQoL. Pharma-
cists’ directive guidance behaviors were used as an indica-
tor of the level of pharmaceutical care.
METHODS: Five ambulatory care pharmacies/clinics
were selected for study participation. A 50-item question-
naire eliciting information about demographics, percep-
tion about pharmacists’ directive guidance behaviors, sat-
isfaction with pharmaceutical care behaviors, compliance
and HRQoL was administered to volunteers at each
study site. A total of 160 patients completed the ques-
tionnaire.
RESULTS: Bivariate correlations showed that directive
guidance behaviors were significantly correlated to pa-
tient satisfaction (r  0.56, p  0.001), and SF-12 Physi-
cal Component Summary (PCS) and Mental Component
Summary (MCS) scores (r  0.19, p  0.05; r 
0.19, p  0.05, respectively). Also, patient satisfaction
was significantly correlated to PCS (r  0.20, p 
0.05). Compliance was significantly correlated to PCS
(r  0.25, p  0.01) and MCS (r  0.23, p  0.01). Two
path analytic models using PCS and MCS as dependent
variables were tested. In path analysis with PCS as the de-
pendent variable, compliance had significant total causal
effect of 0.16 (p  0.05) that was due to its direct effect.
No other path coefficients were significant in this model.
In path analysis with MCS as the dependent variable, no
path coefficients were significant.
